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Gastro-oesophageal reflux disease (GORD) and obesity are associated with frequent exacerbations and 
poor quality of life in asthmatics. Multiple mechanisms have been proposed for the effect of obesity, 
including modification of inflammation affecting epithelial cell proliferation and wound repair, while 
the role of GORD is poorly understood and proton pump inhibitor (PPI) are of variable efficacy. 
GORD might exert a deleterious effect by inducing vagal reflex, neuroinflammation and directly (via 
microaspiration) triggering airway inflammation. Studies of reflux in animal models and human 
bronchial epithelial cell culture show varying impact on inflammation and airway remodelling. We 
have recently demonstrated changes in the sputum proteome in severe asthmatics with GORD, 
providing supportive evidence for gastric secretions exerting a direct effect on the airways (1).  The 
epithelium plays a key role in asthma, so in this study we speculated that severe asthma in obese 
patients with GORD would be associated with epithelial dysfunction. Because GORD is treated with 
PPI, drugs associated with risk of pneumonia and exacerbations of COPD and cystic fibrosis, the 
impact of PPI was also assessed.  
 
We analyzed 61 never or ex-smoker asthmatics and 44 healthy never smokers from the U-BIOPRED 
study (2) who had undergone bronchoscopy, bronchial biopsy and epithelial brushing. Patients were 
categorised as obese if BMI≥30kg/m², having or not a physician’s diagnosis of GORD, and treated or 
not for GORD. Epithelial brushings were processed into RNAlater for Affymetrix U133 Plus 2.0 
microarray analysis (GSE76226) and bronchial biopsies were immunostained for CD3+, CD4+ and 
CD8+ lymphocytes and analysed for basement membrane thickness. The study was approved by 
national ethics committees. All participants provided consent. 
 
Epithelial transcriptomic data were clustered by TDA  using the Ayasdi Core software (Ayasdi, 
MenloPark, CA), with cluster boundaries defined by density using Morse theory (3). Paired t-tests 
were applied to log2 transformed transcriptomic data. Clinical data were analyzed by Kruskal-Wallis, 
Mann-Whitney U or Student t tests depending on data distribution. False discovery rate correction was 
applied to the differentially expressed genes (DEGs). Pathway signatures and upstream regulators 
were identified by Ingenuity Pathway Analysis (IPA) (QIAGEN, Redwood City, CA). Potential drug 
impact on DEGs was identified by Connectivity Map (CMap) analysis of DEG signatures.  
 
TDA analysis produced three clusters of similar size (C1, 2 and 3), comprising 21 participants (34%) 
in C1, 23 (38%) in C2 and 22 (36%) in C3 (Fig 1). When compared to combined C2/3 clusters, C1 had 
a higher incidence of obesity (76% vs 47%, p=0.02), GORD (85% vs 43%, p=0.04) and GORD 
treatment (81% vs 36%, p=0.004) and 48% were obese and had a diagnosis of GORD and GORD 
treatment (compared to 10% in C2/C3, p=0.0009); this cluster was, therefore, termed the Obesity-
GORD-PPI treatment [OGP] phenotype. When compared to C2/3, the OGP cluster had lower blood 
eosinophil counts (p=0.007), but was similar in respect of corticosteroid treatment.  
IPA identified 77 pathways dysregulated in the OGP cluster relative to health, the top being the 
WNT/β-catenin pathway (z-score: 2.2-fold difference vs. healthy participants). Amongst the 38 DEGs 
related to WNT/β-catenin signalling, FZD3 and WISP1 were amongst the top upregulated (Figure 1). 
Application of CMap analysis to these DEGs and comparison with the genes regulated by PPI and bile 
acids in A549 epithelial cells (Fig 1) showed that the WNT/β-catenin signalling pathway was not 
associated with PPI or bile acid effects. Furthermore, although evidence points to WNT/β-catenin 
signalling and the WNT target gene WISP1 regulating airway remodelling and pulmonary 
myofibroblast proliferation in COPD and IPF (4), we did not find a difference in the thickness of the 
sub-epithelial lamina reticularis  between the OGP cluster and the other patients.  
WISP1 has been shown to be upregulated in obese individuals but has also been identified as an 
inhibitor of adipocyte differentiation by blocking the induction of the adipogenic transcription factors 
PPARγ and C/EBPα (5), both of which were downregulated in the OGP cluster. Given that PPARγ 
expression in bronchial epithelial cells has been shown to protect against oxidative stress and suppress 
MUC5AC expression, these data suggested that the OGP phenotype should be associated with airways 
inflammation. However, our study showed that the OGP cluster had a predominantly pauci-
granulocytic sputum cell profile (p=0.017) and fewer sub-mucosal T-cells when compared to health 
(CD8+ cells: 10.2 vs. 20.4 cells/mm², p=0.05; CD4+ cells: 7.2 vs 10.4, p=0.02; CD3+ cells: 23.0 vs 
36.7, p=0.03). This could be explained by the finding in the OGP cluster of downregulated immune 
response pathways, including proliferation, activation and survival of lymphocytes, leucocyte 
recruitment and transepithelial migration (IL-7, TREM1 (Triggering receptor expressed on myeloid 
cells 1), B cell receptor and Calcium signaling; z-scores -0.69, -2.18, -2.33, -3.66 respectively). When 
compared to health and C2/3, the OGP cluster also exhibited downregulation of CCL5, CXCL1 and 
CCL11. CMap analysis identified high connectivity scores between TREM1 and effects of bile acids 
(CMap score 99.2), and between PPI treatment and Calcium signaling (CMap score 76.6) (Fig 1), 
suggesting a direct impact of bile acids and PPI treatment on immune cell accumulation.  
In support of our study, recent analysis of bile acid effects on LPS-stimulated macrophages identified 
downregulated genes involved in differentiation and migration of immune cells, including T-cells, and 
decreased chemokine expression, including CCL5 and CXCL1 (6). PPI-inhibition of H+/K+ ATPase 
induces intracellular acidification that inhibits immune cell proliferation, decreases heparanase 
activation involved in ECM remodeling and degradation (7), and decreases intercellular adhesion 
molecule expression, resulting in reduced immune cell transmigration (8). In airway epithelial cells, 
TLR2 activation by DAMPs releases calcium from endoplasmic reticulum stores, resulting in 
chemokine regulation through activation of NFκB and calpains which cleave junctional proteins and 
facilitate immune cell transmigration (9). In our study, expression of TLR2, NFκB and NFκB-
regulated chemokines (CCL5, CXCL1, CXCL2, CCL11, CCL22, CXCL8) was also downregulated in 
the OGP cluster. In contrast, expression of calreticulin and calnexin, two endoplasmic reticulum 
calcium storage proteins, whose expression is increased by low intracellular calcium storage (10), was 
upregulated in the OGP cluster, suggesting dysregulated intracellular calcium influx. This could be 
speculated to involve PPI-induced decrease of Ca2+-ATPase sensitivity as previously shown in 
myocytes (11).  
The top upstream regulator for the OGP cluster was CD24 (activation z-score 2.2; p=0.0004), a cell 
surface receptor involved in suppression of immune responses to DAMPs (12), organization of tight 
junction proteins (13), regulation of adipogenesis, B-cell survival and T-cell activity (14). CD24 is a 
direct WNT target gene (15), which is consistent with our findings of upregulated WNT/β catenin 
signaling. Together, these associations suggest a central role for CD24 in the OGP phenotype. 
In summary, this exploratory analysis of epithelial gene expression in severe asthma has identified 3 
clusters, one of which is enriched for obesity, GORD and treatment with PPI, with an as yet 
unreported mechanism that could represent a new endotype. This potentially new endotype was shown 
to be pauci-granulocytic as a consequence of downregulated mechanisms of cell recruitment linked to 
bile acid exposure and PPI treatment. The implications of this endotype for virus-induced 
exacerbations, which are increased in asthmatics with GORD, remains to be elucidated.  
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Severe asthma clusters based on epithelial transcriptomics. (a) TDA network constructed with 
transcripts from bronchial brushings using density analysis by Morse theory, with (b) the identified 
clusters 1-3 colored yellow, pink and orange. (c-e) Applying BMI, GORD treatment and blood 
eosinophil counts as meta data, nodes are colored by intensity from blue (low intensity) to red (high 
intensity). (f) Heat map of the three top upregulated and three top downregulated differentially 
expressed genes of WNT/β-catenin, TREM1 and Calcium signalling in the OGP cluster and in airway 
epithelial cells exposed to PPI (column L for Lansoprazole and column R for Rabeprazole) and bile 
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